B. Allard

发表

Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptor

F. Ducancel, D. Boquet, J. Couraud, 2013, mAbs.

Electroporation-aided DNA immunization generates polyclonal antibodies against the native conformation of human endothelin B receptor.

F. Ducancel, D. Boquet, J. Couraud, 2011, DNA and cell biology.

CD73-Generated Adenosine: Orchestrating the Tumor-Stroma Interplay to Promote Cancer Growth

Martin Turcotte, J. Stagg, B. Allard, 2012, Journal of biomedicine & biotechnology.

Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays.

Kathleen M Spring, I. Cousineau, J. Stagg, 2019, Methods in enzymology.

Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasis

L. Buisseret, D. Allard, P. Chrobak, 2019, Oncoimmunology.

A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment

S. Antonia, A. Chiappori, J. Stagg, 2017, Neoplasia.

Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies.

D. Allard, J. Stagg, B. Allard, 2016, Methods in molecular biology.

Targeting the CD73-adenosine axis in immuno-oncology.

D. Allard, P. Chrobak, N. Messaoudi, 2019, Immunology letters.

Immunosuppressive activities of adenosine in cancer.

P. Darcy, P. Beavis, J. Stagg, 2016, Current opinion in pharmacology.

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial

C. Sotiriou, S. Loi, K. Willard-Gallo, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Human Immunodeficiency Virus Infection Transcriptase Inhibitor for Treatment of Deoxycytidine Nucleoside Reverse Toxicity Profile of SPD 754 , a New In Vitro Antiretroviral Activity and In Vitro

D. Taylor, B. Allard, P. McKenna, 2005 .

CD73 Promotes Chronic Lymphocytic Leukemia

N. Johnson, D. Allard, P. Chrobak, 2022, Cancers.

CD73 Plays a Protective Role in Collagen-Induced Arthritis

P. Chrobak, Roxanne Charlebois, J. Stagg, 2015, The Journal of Immunology.

On the mechanism of anti-CD39 immune checkpoint therapy

D. Allard, J. Stagg, B. Allard, 2020, Journal for ImmunoTherapy of Cancer.

Targeting the adenosine pathway for cancer immunotherapy.

D. Allard, J. Stagg, B. Allard, 2019, Seminars in immunology.

The adenosine pathway in immuno-oncology

L. Buisseret, D. Allard, J. Stagg, 2020, Nature Reviews Clinical Oncology.

Anti‐CD73 therapy impairs tumor angiogenesis

Kathleen M Spring, Martin Turcotte, J. Stagg, 2014, International journal of cancer.

Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.

M. Smyth, D. Mittal, A. Young, 2014, Cancer research.

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

S. Robson, M. S. Longhi, J. Stagg, 2017, Immunological reviews.

Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer

Martin Turcotte, J. Stagg, B. Allard, 2014, Expert opinion on therapeutic targets.

In Vitro Antiretroviral Activity and In Vitro Toxicity Profile of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor for Treatment of Human Immunodeficiency Virus Infection

D. Taylor, R. Bethell, N. Nguyen-ba, 2006, Antimicrobial Agents and Chemotherapy.

1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer

R. Deberardinis, Russell G. Jones, P. Watson, 2020, Science Advances.

Immuno-oncology-101: overview of major concepts and translational perspectives.

C. Sotiriou, M. Kok, C. Solinas, 2018, Seminars in cancer biology.

PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors.

L. Buisseret, D. Allard, P. Chrobak, 2017, Cancer research.

CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer

F. Saad, Roxanne Charlebois, J. Stagg, 2015, Clinical Cancer Research.

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

M. Smyth, J. Stagg, B. Allard, 2013, Clinical Cancer Research.

WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors

F. Saad, K. Do, P. Gaudreau, 2019, Oncoimmunology.

Kinetic Study of Human Full-Length Wild-Type JAK2 and V617F Mutant Proteins

D. Erdmann, F. Hofmann, P. Chène, 2009 .

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

S. Loi, P. Darcy, P. Beavis, 2015, Cancer Immunology Research.

Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects

J. Stagg, B. Allard, 2013, Therapeutic advances in medical oncology.

CD73-adenosine: a next-generation target in immuno-oncology.

P. Gaudreau, D. Allard, P. Chrobak, 2016, Immunotherapy.

Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration

P. Robin, D. Leiber, F. Ducancel, 2016, mAbs.

Cancer Therapy: Preclinical TargetingCD73Enhances theAntitumorActivity of Anti-PD-1 and Anti-CTLA-4 mAbs

M. Smyth, J. Stagg, B. Allard, 2013 .

Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis

M. Smyth, D. Mittal, A. Young, 2014, Oncoimmunology.

CD73-adenosine reduces immune responses and survival in ovarian cancer patients

P. Gaudreau, Martin Turcotte, J. Stagg, 2016, Oncoimmunology.

Assessing the Efficacy of Immune Checkpoint Inhibitors in Preclinical Tumor Models.

D. Allard, J. Stagg, B. Allard, 2023, Methods in molecular biology.

Electrotransfer of cDNA coding for a heterologous prion protein generates autoantibodies against native murine prion protein in wild-type mice.

F. Dkhissi, D. Boquet, J. Couraud, 2010, DNA and cell biology.

CD73 inhibits cGAS-STING and cooperates with CD39 to promote pancreatic cancer.

Benjamin Haibe-Kains, S. Turcotte, D. Allard, 2022, Cancer immunology research.

Publisher Correction: The adenosine pathway in immuno-oncology

L. Buisseret, D. Allard, J. Stagg, 2020, Nature Reviews Clinical Oncology.

The CD73 immune checkpoint promotes tumor cell metabolic fitness

E. Ma, D. Allard, I. Cousineau, 2022, bioRxiv.

28PClinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial

C. Sotiriou, L. Buisseret, M. Piccart-Gebhart, 2017 .

Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma

L. Buisseret, D. Allard, P. Chrobak, 2023, Cell reports. Medicine.